

TEVA PHARMACEUTICAL INDUSTRIES LTD  
Form 6-K  
November 30, 2004

**FORM 6-K**

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934**

For the month of November 2004

Commission File Number 0-16174



- 1 -

**Teva Pharmaceutical Industries Limited**

(Translation of registrant's name into English)

**5 Basel Street, P.O. Box 3190**

**Petach Tikva 49131 Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b):  
82- \_\_\_\_\_



Teva Pharmaceutical Industries Ltd.

Web Site: [www.tevapharm.com](http://www.tevapharm.com)

---

Contact: Dan Suesskind

Chief Financial Officer

Teva Pharmaceutical Industries Ltd.

(011) 972-2-589-2840

Bill Fletcher

President and CEO

Teva North America

**FOR IMMEDIATE RELEASE** (215) 591-8800

Dorit Meltzer

Director, Investor Relations

Teva Pharmaceutical Industries Ltd.

(011) 972-3-926-7554

**Teva Announces Promotions  
and Additions to its Management Team**

**Jerusalem, Israel, November 30, 2004** - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today a number of management promotions, as well as the addition of new executive talent to its management team. These appointments are part of the continuing process of development of management capacity designed to keep pace with rapid growth.

Mr. William Fletcher, currently President and CEO - Teva North America, will assume a new role as Chairman - Teva North America. Mr. George Barrett, currently President and CEO of Teva Pharmaceuticals USA, will be promoted to the position of President and CEO - Teva North America and Teva Group Vice President, and Mr. William Marth, currently Executive Vice President of Teva USA, will be promoted to the position of President and CEO of Teva Pharmaceuticals USA, Inc.

Mr. Israel Makov, President and CEO of Teva Pharmaceutical Industries Ltd., said: "Acknowledging Bill Fletcher's outstanding service to the Company for more than 20 years, I am very pleased that Bill, in his new role, will continue to devote his time and immense experience to support Teva's strategies and initiatives both in North America and on a global basis. In this way, we are also respecting Bill's request to allow him more time for personal pursuits."

Mr. Makov continued: "George Barrett, who has led Teva USA through a period of unprecedented growth, will now apply his talents and experience to the entire range of activities of Teva North America as well as contributing to our global leadership team. I am also confident that Bill Marth, who successfully executed Teva USA's commercial strategy, will do an excellent job as the leader of the largest generic drug company in the United States."

Mr. Amir Elstein has been appointed to the position of Teva Group Vice President for Biogenerics and a member of the core management team. Mr. Elstein has been employed by Intel Corporation since 1982 and most recently served as General Manager of Intel Electronics Ltd, Jerusalem. He served as a member of the Board of Directors of Teva from 1995 to 2004. Prior to his appointment as an officer of Teva, he stepped down as a member of its Board. "Amir brings with him a wealth of management and operational experience and will focus on the emerging field of biogenerics," said Israel Makov.

Mr. Marvin Samson will assume the role of Teva's Group Vice President for Injectables. Mr. Makov said: "With the increased importance of injectables in Teva's global portfolio, Marvin will fully focus his talents and attention in this field, contributing his tremendous expertise in this area to the injectable businesses throughout Teva."

Mr. Aharon (Arik) Yaari, Vice President for the Active Pharmaceutical Ingredients (API) division, will join Teva's core management team. Mr. Makov remarked: "I would like to acknowledge Arik's contribution and am confident of the strength he will add to the strategic leadership of Teva."

These appointments will become effective as of January 1, 2005.

Additionally, two new Vice Presidents, Dr. Shmuel (Muli) Ben-Zvi and Mr. Doron Blachar, have been appointed to Teva's finance division, reporting to Dan Suesskind, Teva's Chief Financial Officer. "These appointments reflect the importance we place on continued excellence in financial management of a high-growth global company," said Israel Makov.

Furthermore, three new country managers in new markets for Teva, in Europe, were appointed: Mr. Manuel Plaza in Spain, Mr. Bruno Barcelos in Portugal and Mr. Peter Burestedt in Sweden. "I wish to welcome these new executives to the Teva team" said Israel Makov, "and I am encouraged by the European reach these appointments signify."

Mr. Makov concluded: "Continuity of management, and the ability to develop, promote and attract executive talent is a key strength of our Company. These changes reflect the importance we attribute to the capacity and expertise of the Teva leadership team and our unwavering commitment to achieving excellence in management."

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe.



*Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products (so called "authorized generics") or successfully extend the exclusivity period of their branded products, the effects of competition on Copaxone® sales, including potential competition from the expected launch of Tysabri®/Antegren®, Teva's ability to rapidly integrate the operations of acquired businesses, including its acquisition of Sicor Inc., regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to completion of appellate litigation, including that relating to Neurontin, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.*

Teva Pharmaceutical Industries Ltd.

Web Site: [www.tevapharm.com](http://www.tevapharm.com)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

By: /s/ Dan Suesskind

Name: Dan Suesskind  
Title: Chief Financial Officer

Date: November 30, 2004



